Company Description
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma.
The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons.
Axogen, Inc. is headquartered in Alachua, Florida.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 452 |
| CEO | Michael Dale |
Contact Details
Address: 13631 Progress Boulevard, Suite 400 Alachua, Florida 32615 United States | |
| Phone | 386 462 6800 |
| Website | axogeninc.com |
Stock Details
| Ticker Symbol | AXGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000805928 |
| CUSIP Number | 05463X106 |
| ISIN Number | US05463X1063 |
| Employer ID | 41-1301878 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Michael D. Dale | President, Chief Executive Officer and Director |
| Marc A. Began | Executive Vice President, General Counsel and Chief Compliance Officer |
| Jens Schroeder Kemp | Chief Marketing Officer |
| Karen Zaderej | Advisor |
| Erick DeVinney | Chief Innovation Officer |
| Craig A. Swandal | Vice President of Operations |
| Harold D. Tamayo M.B.A. | Vice President of Finance and Investor Relations |
| Doris Quackenbush | Vice President of Sales |
| Dr. Ivica Ducic M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| May 2, 2025 | SCHEDULE 13G/A | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 144 | Filing |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |